Greenwich LifeSciences wins UK regulatory clearance to expand FLAMINGO-01 trial - GLSI News | RalliesGreenwich LifeSciences wins UK regulatory clearance to expand FLAMINGO-01 trial
G
GLSI• UK clearance expands FLAMINGO-01 trial
- Greenwich Lifesciences won UK regulatory clearance to expand its Phase III FLAMINGO-01 breast cancer recurrence trial into the United Kingdom.
- The authorization adds 5-10 potential UK sites to roughly 170-180 active sites across the US and Europe.
- The company is working with The Royal Marsden to advance site start-up and oversight in the UK.
CHCO
•
